BBHC
ASND icon

Brown Brothers Harriman & Co’s Ascendis Pharma A/S ASND Stock Holding History

Brown Brothers Harriman & Co’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-80
Closed -$8K – 1266
2022
Q3 		$8K Buy
+80
New +$7.58K ﹤0.01% 1192

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Brown Brothers Harriman & Co's ASND Position: Q4 2022 in Review

Brown Brothers Harriman & Co sold out of Ascendis Pharma A/S (ASND) in Q4 2022, closing a stake of 80 shares — an estimated $8K sold.

Brown Brothers Harriman & Co first reported a position in ASND in Q3 2022 and held it in 1 quarter. The position peaked at $8K in Q3 2022. 187 funds tracked by Wall St. Rank hold ASND as of Q4 2022.

  • Brown Brothers Harriman & Co reported no remaining Ascendis Pharma A/S position as of Q4 2022 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 80 Ascendis Pharma A/S shares in Q4 2022, an estimated $8K.
  • Brown Brothers Harriman & Co first reported a position in Ascendis Pharma A/S in Q3 2022 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's Ascendis Pharma A/S position peaked at $8K in Q3 2022.
  • 187 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2022.

Based on Brown Brothers Harriman & Co's 13F filing for Q4 2022, filed 9 Feb 2023.